A Very Large-Scale Microfluidic Integration (VLSMI) chip for producing lipid nanoparticles (LNPs) for RNA vaccines and therapeutics
用于生产用于 RNA 疫苗和治疗药物的脂质纳米颗粒 (LNP) 的超大规模微流控集成 (VLSMI) 芯片
基本信息
- 批准号:10546406
- 负责人:
- 金额:$ 29.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-04 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentArchitectureAreaBiological ProductsCOVID-19COVID-19 pandemicCOVID-19 testCardiovascular systemCellsClinicalCommunicable DiseasesCyclic GMPDevelopmentDevice DesignsDevicesDisease OutbreaksDoseDrug Delivery SystemsEffectivenessElementsEncapsulatedEnsureEvaluationFormulationGenerationsGlassGrowthHumanIndividualIndustrializationInstructionLengthLiquid substanceMapsMethodsMicrofluidicsModelingNucleic AcidsPatientsPharmacologic SubstancePhasePlantsPlayPoly CProblem SolvingProcessProductionPropertyPublic HealthRNARNA deliveryRNA vaccineScientific Advances and AccomplishmentsScientistSiliconSpeedSterilitySystemTechnologyTherapeuticTimeTimeLineTransistorsTranslationsVaccine ProductionVaccinesbasecancer immunotherapycancer therapyclinical translationcostdelivery vehicledesigndrug developmentemerging pathogenflexibilityfluorescence imaginggene therapyimprovedinterestlipid nanoparticlemicrochipnew technologynovel therapeuticsnovel vaccinespolydimethylsiloxaneportabilityresponsesuccesstherapeutic RNA
项目摘要
Abstract
Infini Fluidics is developing a Very Large-Scale Microfluidic Integration (VLSMI) chip for producing lipid
nanoparticles (LNPs) for RNA therapeutics that can be scaled by a dynamic range of 1000x—from 100 mL/hr to
100 L/hr—thus enabling efficient and affordable use across all phases of drug development. LNPs are promising
drug delivery vehicles that have been critical in the clinical translation of RNA therapeutics and vaccines, most
notably the COVID-19 mRNA vaccines produced by Pfizer and Moderna. The COVID-19 pandemic has created
unprecedented demand for rapid production of LNPs on a global scale, and this has highlighted some of the
major limitations of current production methods. Indeed, a key challenge toward the broad clinical translation of
LNP-based RNA therapeutics and vaccines is the development of formulation strategies that can robustly
produce precisely defined formulations while accommodating scalable throughputs ranging from early
development to clinical translation.
To solve this problem, Infini Fluidics is developing the VLSMI chip, enabling scaling of production by 1000-fold
while maintaining the potency typical of LNPs generated using microfluidics, thus enabling efficient and
affordable production of high-quality LNPs across the phases of drug development. Infini’s proposed VLSMI
architecture integrates tens to hundreds of microfluidic mixing units onto a single, 4-inch silicon chip, just like
transistors in a computer chip. The individual mixing units allow unprecedented control of LNP physiochemical
and functional properties, while hundreds of these units allow flexible manufacturing of LNPs for clinical-phase
trials or industrial-scale manufacturing.
The specific aims of this Phase I project are 1: To evaluate the mixing efficiency of staggered herringbone mixing
(SHM) design units at various lengths and flow rates using fluorescent images, Infini will evaluate four different
device designs, implemented in silicon and glass, which is more compatible with the stringent requirements of
pharmaceutical manufacturing. Mixing dynamics will be evaluated to identify the best performing SHM designs
to synthesize LNPs, and 2: To evaluate LNP properties to determine the uniformity of the LNPs by encapsulating
poly(C) as a model nucleic acid; here, Infini will evaluate LNP properties to demonstrate LNP production is
predictable and accurate for commercial scale.
Infini Fluidics’ VLSMI chip solution will enable the fine control over LNP physiochemical and functional properties
that is necessary for high LNP quality and potency and that has so far eluded macroscale LNP production
methods. This technology can be widely applied to accelerate the development, evaluation, and distribution of
RNA-based therapeutics and vaccines, helping to grow this burgeoning and promising field. This will enable
success in new therapeutic areas and allow a timelier response to emerging pathogens.
摘要
Infini Fluidics正在开发用于生产脂质的超大规模微流控集成(VLSMI)芯片
用于RNA治疗的纳米颗粒(LNP),其可以通过1000倍的动态范围缩放-从100 mL/hr到100 mL/hr,
100 L/hr-从而能够在药物开发的所有阶段有效且经济地使用。LNP很有前途
在RNA治疗和疫苗的临床转化中至关重要的药物递送载体,
特别是辉瑞和Moderna生产的COVID-19 mRNA疫苗。2019冠状病毒病大流行造成了
在全球范围内对LNP的快速生产的前所未有的需求,这突出了一些
目前生产方法的主要局限性。事实上,对广泛的临床翻译的一个关键挑战是,
基于LNP的RNA治疗剂和疫苗是可以稳健地
生产精确定义的配方,同时适应可扩展的吞吐量,
发展到临床翻译。
为了解决这个问题,Infini Fluidics正在开发VLSMI芯片,使生产规模扩大1000倍
同时保持使用微流体产生的LNP的典型效力,从而使得能够有效和
在药物开发的各个阶段,以负担得起的价格生产高质量的LNP。Infini的VLSMI
这种架构将数十到数百个微流体混合单元集成到一个4英寸的硅芯片上,就像
计算机芯片中的晶体管。单独的混合装置可对LNP的理化性质进行前所未有的控制
和功能特性,而数百个这样的单元可以灵活地制造临床阶段的LNP
试验或工业规模生产。
本项目的具体目标是:1.评价交错人字形搅拌的搅拌效率
(SHM)设计单位在不同的长度和流速使用荧光图像,英菲尼将评估四个不同的
器件设计,在硅和玻璃中实现,更符合
制药业。将对混合动力学进行评估,以确定性能最佳的SHM设计
2:评价LNP性质以通过包封LNP来确定LNP的均匀性
poly(C)作为模型核酸;在这里,Infini将评估LNP特性,以证明LNP生产是
可预测和准确的商业规模。
Infini Fluidics的VLSMI芯片解决方案将实现对LNP理化和功能特性的精细控制
这是高LNP质量和效力所必需的,并且迄今为止还没有大规模LNP生产
方法.这项技术可以广泛应用于加速开发,评估和分发
基于RNA的疗法和疫苗,有助于发展这一新兴和有前途的领域。这将使
在新的治疗领域取得成功,并允许对新出现的病原体作出更及时的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sagar Prasad Yadavali其他文献
Sagar Prasad Yadavali的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 29.34万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 29.34万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 29.34万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 29.34万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 29.34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 29.34万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 29.34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 29.34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 29.34万 - 项目类别: